Leptomycin

WikiDoc Resources for Leptomycin
Articles
Most recent articles on Leptomycin Most cited articles on Leptomycin Review articles on Leptomycin Articles on Leptomycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Leptomycin Images of Leptomycin Photos of Leptomycin Podcasts & MP3s on Leptomycin Videos on Leptomycin
Evidence Based Medicine
Cochrane Collaboration on Leptomycin Bandolier on Leptomycin TRIP on Leptomycin
Clinical Trials
Ongoing Trials on Leptomycin at Clinical Trials.gov Trial results on Leptomycin Clinical Trials on Leptomycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Leptomycin NICE Guidance on Leptomycin NHS PRODIGY Guidance FDA on Leptomycin CDC on Leptomycin
Books
Books on Leptomycin
News
Leptomycin in the news Be alerted to news on Leptomycin News trends on Leptomycin
Commentary
Blogs on Leptomycin
Definitions
Definitions of Leptomycin
Patient Resources / Community
Patient resources on Leptomycin Discussion groups on Leptomycin Patient Handouts on Leptomycin Directions to Hospitals Treating Leptomycin Risk calculators and risk factors for Leptomycin
Healthcare Provider Resources
Symptoms of Leptomycin Causes & Risk Factors for Leptomycin Diagnostic studies for Leptomycin Treatment of Leptomycin
Continuing Medical Education (CME)
CME Programs on Leptomycin
International
Leptomycin en Espanol Leptomycin en Francais
Business
Leptomycin in the Marketplace Patents on Leptomycin
Experimental / Informatics
List of terms related to Leptomycin

Leptomycin B is a secondary metabolite produced by Streptomyces spp.

Leptomycin B (LMB) was originally discovered as a potent anti-fungal antibiotic. Leptomycin B was found to cause cell elongation of the fission yeast Schizosaccharomyces pombe. Since then this elongation effect is being used for the bioassay of Leptomycin. However, recent data (2003) showed that Leptomycin causes G1 cell cycle arrest in mammalian cells and is a potent anti-tumor agent against murine experimental tumors

Therefore Leptomycin B became a potent and specific nuclear export inhibitor. Leptomycin B alkylates and inhibits CRM1 (chromosomal region maintenance)/exportin 1 (XPO1), a protein required for nuclear export of proteins containing a nuclear export sequence (NES). In addition to antifungal and antibacterial activities, Leptomycin B blocks the cell cycle and is a potent anti-tumor agent. At low nM concentrations, Leptomycin B blocks the nuclear export of many proteins including HIV-1 Rev, MAPK/ERK, and NF-κB/IκB, and it stabilizes the expression of p53. Leptomycin B also inhibits the export and translation of many RNAs, including COX-2 and c-Fos mRNAs, by inhibiting export of ribonucleoproteins.

Leptomycin A (LPA) was discovered together with LMB. LMB is twice as potent as LPA.

References

• Hamamoto T, Seto H, Beppu T. Leptomycins A & B, new antifungal antibiotics. The Journal of Antibiotics. 1983, 36: 646-650.

External links

• leptomycin+B at the US National Library of Medicine Medical Subject Headings (MeSH)

Original data copied with permission from Leptomycin B manufacturer product page (Fermentek)

Template:WikiDoc Sources